European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.3.3. Long-term immunosuppression. Toxicity of immunosuppression.
A. Careful long-term monitoring of graft recipients is mandatory to discover signs of immunosuppressive drug toxicity, in particular nephrotoxicity. B. In the case of a discrepancy between the drug dose and signs of toxicity, then a thorough pharmacokinetic analysis should be performed. C. Cardiovascular, renal and metabolic risks and the risk of de novo malignancy must be considered in a long-term monitoring programme.
D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D007668:Kidney / Q000187:drug effects; D016030:Kidney Transplantation / Q000009:adverse effects*
D007166:Immunosuppressive Agents